Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model

• Published in: The FASEB journal 2008-12, Vol.22 (12), p.4179-4189
• Main Authors: Schmieder, Anne H, Caruthers, Shelton D, Zhang, Huiying, Williams, Todd A, Robertson, J. David, Wickline, Samuel A, Lanza, Gregory M
• Format: Article
• Language: English
• Subjects: antiangiogenic; cancer; fumagillin; magnetic resonance imaging; molecular imaging; Research Communications
• ISSN: 0892-6638; 1530-6860
• DOI: 10.1096/fj.08-112060

Our objectives were 1) to characterize angiogenesis in the MDA-MB-435 xenograft mouse model with three-dimensional (3D) MR molecular imaging using α₅β₁(RGD)- or irrelevant RGS-targeted paramagnetic nanoparticles and 2) to use MR molecular imaging to assess the antiangiogenic effectiveness of α₅β₁(ανβ₃)- vs. ανβ₃-targeted fumagillin (50 μg/kg) nanoparticles. Tumor-bearing mice were imaged with MR before and after administration of either α₅β₁(RGD) or irrelevant RGS-paramagnetic nanoparticles. In experiment 2, mice received saline or α₅β₁(ανβ₃)- or ανβ₃-targeted fumagillin nanoparticles on days 7, 11, 15, and 19 posttumor implant. On day 22, MRI was performed using α₅β₁(ανβ₃)-targeted paramagnetic nanoparticles to monitor the antiangiogenic response. 3D reconstructions of α₅β₁(RGD)-signal enhancement revealed a sparse, asymmetrical pattern of angiogenesis along the tumor periphery, which occupied 0.05). Reduction of angiogenesis in MDA-MB-435 tumors from low to negligible levels did not decrease tumor volume. MR molecular imaging may be useful for characterizing tumors with sparse neovasculature that are unlikely to have a reduced growth response to targeted antiangiogenic therapy.--Schmieder, A. H., Caruthers, S. D., Zhang, H., Williams, T. A., Robertson, J. D., Wickline, S. A., Lanza, G. M. Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.